News and Press
Syntaxin Expands its Strategic Alliance with Allergan for Novel Therapeutic Compounds
News
SEP
2006
Syntaxin have entered into a second exclusive research and license arrangement with Allergan to design and develop novel clostridial endopeptidase-based compounds.
Syntaxin Ltd (Syntaxin), a biopharmaceutical company focusing on designing and developing bacterial-based therapeutic proteins for the treatment of neurological, respiratory and metabolic diseases, today announced that the company has entered into a second exclusive research and license arrangement with Allergan to design and develop novel clostridial endopeptidase-based compounds. This new agreement builds on Syntaxin and Allergan's successful collaboration in the field of pain, by expanding the joint programmes to include other types of nerve cell.
Under this agreement, Syntaxin and Allergan will jointly fund research efforts utilising Syntaxin's proprietary technology to engineer clostridial endopeptidase-based proteins that are specific for target cells and thus have potential use as therapeutics within the agreed field. The terms of the deal include up-front and milestone payments to Syntaxin, along with royalties paid to Syntaxin upon commercialisation by Allergan of any compounds developed out of the collaboration.
Independently, Syntaxin will continue to invest in the research and development of novel pharmaceuticals based upon pharmacologically active bacterial proteins for use in other therapeutic areas such as respiratory and metabolic diseases.
Patrick Doyle, Chief Executive Officer of Syntaxin, in announcing this collaboration said: "We have established a very successful partnership with Allergan in the field of pain, and we are delighted to be able to broaden our collaboration in this second major alliance. The combination of our technology for the engineering and highly specific targeting of pharmacologically-active bacterial proteins with the clinical, commercial and scientific expertise of Allergan creates a very powerful tool for the development of innovative medicines that can further address significant unmet patient need."